Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Pulse Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.19 |
52 Week High | US$14.96 |
52 Week Low | US$3.78 |
Beta | 1.76 |
11 Month Change | -11.33% |
3 Month Change | 28.47% |
1 Year Change | 55.63% |
33 Year Change | -35.13% |
5 Year Change | -14.38% |
Change since IPO | 168.35% |
Recent News & Updates
Pulse Biosciences Stock: Signs Of Life Following Q1 Update
May 16We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
May 10Recent updates
Pulse Biosciences Stock: Signs Of Life Following Q1 Update
May 16We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
May 10We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Dec 25We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Sep 04Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?
Mar 08Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO
Sep 20Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky
Apr 04Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?
Oct 29Pulse Biosciences gets Health Canada approval for CellFX System
Jun 09Is Pulse Biosciences (NASDAQ:PLSE) In A Good Position To Invest In Growth?
Mar 31Who Has Been Buying Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?
Feb 24Pulse Biosciences establishes at-the-market equity program
Feb 04What Percentage Of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Do Insiders Own?
Jan 20Pulse Biosciences' CellFX System U.S. application moves forward for general dermatology indication
Jan 12We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Dec 16Shareholder Returns
PLSE | US Medical Equipment | US Market | |
---|---|---|---|
7D | 4.2% | -0.8% | 0.04% |
1Y | 55.6% | -2.8% | 20.7% |
Return vs Industry: PLSE exceeded the US Medical Equipment industry which returned -1.3% over the past year.
Return vs Market: PLSE exceeded the US Market which returned 22.5% over the past year.
Price Volatility
PLSE volatility | |
---|---|
PLSE Average Weekly Movement | 15.3% |
Medical Equipment Industry Average Movement | 8.1% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: PLSE's share price has been volatile over the past 3 months.
Volatility Over Time: PLSE's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 56 | Burke Barrett | www.pulsebiosciences.com |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
Pulse Biosciences, Inc. Fundamentals Summary
PLSE fundamental statistics | |
---|---|
Market cap | US$608.03m |
Earnings (TTM) | -US$42.55m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-14.5x
P/E RatioIs PLSE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PLSE income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$42.55m |
Earnings | -US$42.55m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.77 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did PLSE perform over the long term?
See historical performance and comparison